ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

ISA Pharmaceuticals will move to BioPartner 5

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer

ISA Pharmaceuticals announces CervISA publication

ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank

ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velders